MAB5308
Anti-BACE Antibody, CT, clone 61-3E7
clone 61-3E7, Chemicon®, from mouse
Synonym(s):
ASP2, BACE1, Beta Secretase, beta-Site APP Cleaving Enzyme
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
61-3E7, monoclonal
species reactivity
primate, mouse, human, rat
manufacturer/tradename
Chemicon®
technique(s)
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... BACE1(23621)
General description
Alzheimer′s disease (AD) is characterized by the progressive formation in the brain of insoluble amyloid plaques and vascular deposits consisting of the 4-kD amyloid b-peptide (Ab). Ab generation is initiated by proteolytic cleavage of the amyloid precursor protein (APP) at the N-terminal of Ab by b-secretase. The Ab peptide is then released by proteolytic cleavage at its C-terminus by g-secretase. Because both these proteases are prime candidates for therapeutic intervention, an intense search has been underway to identify these two enzymes.A human transmembrane aspartic-protease (Asp2), referred to as BACE, has been characterized and shown to have all the properties of b-secretase. Four groups in all have now confirmed that BACE (or Asp2) is a convincing candidate for b-secretase.
BACE is an N-glycosylated integral membrane aspartyl protease with Mr=70 kDa. Mature BACE is produced from the immature form through a series of post-translational proteolytic cleavages and glycosylation. Sequence analysis has revealed that the immature form of BACE contains an N-terminal signal sequence (residues 1-21) followed by a large catalytic domain, a single transmembrane domain (residues 461-477), and a short cytoplasmic domain (residues 478-501). The signal sequence (1-21) is cleaved from the immature form by a signal peptidase located in the endoplasmic reticulum (ER), yielding the proBACE protein (Mr=75 kDa) which starts at residue 22. The proBACE protein is modified by cleavage of 24 N-terminal residues (aa 22-45), producing the mature BACE protein.
BACE is an N-glycosylated integral membrane aspartyl protease with Mr=70 kDa. Mature BACE is produced from the immature form through a series of post-translational proteolytic cleavages and glycosylation. Sequence analysis has revealed that the immature form of BACE contains an N-terminal signal sequence (residues 1-21) followed by a large catalytic domain, a single transmembrane domain (residues 461-477), and a short cytoplasmic domain (residues 478-501). The signal sequence (1-21) is cleaved from the immature form by a signal peptidase located in the endoplasmic reticulum (ER), yielding the proBACE protein (Mr=75 kDa) which starts at residue 22. The proBACE protein is modified by cleavage of 24 N-terminal residues (aa 22-45), producing the mature BACE protein.
Specificity
Reacts with BACE (beta-site APP Cleaving Enzyme). Shows no reactivity to BACE2 by Western blot.
Immunogen
Epitope: C-terminus
Synthetic peptide corresponding to the C-terminus of human BACE.
Application
Detect BACE using this Anti-BACE Antibody, C-terminus, clone 61-3E7 validated for use in IP & WB.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Western blotting: 1 μg/mL; recognizes pro and mature forms: ~60-75kDa on reducing westerns. BACE is N-terminally glycosylated which causes the wide size range.
Immunohistochemistry on paraformaldehyde fixed tissues from human, rat, mouse and monkey.
Immunocytochemistry on cells expressing BACE. Acetone or methanol fixation preferred; 4% PFA 5′, RT followed by 0.1% triton X-100 1 hour, can also be used. 1:200-1:500 is recommended, optimization is necessary.
Immunoprecipitation:
Optimal working dilutions must be determined by end user.
Immunohistochemistry on paraformaldehyde fixed tissues from human, rat, mouse and monkey.
Immunocytochemistry on cells expressing BACE. Acetone or methanol fixation preferred; 4% PFA 5′, RT followed by 0.1% triton X-100 1 hour, can also be used. 1:200-1:500 is recommended, optimization is necessary.
Immunoprecipitation:
Optimal working dilutions must be determined by end user.
Target description
~ 60-75 kDa
Physical form
Format: Purified
Protein A purified
Purified immunoglobulin. Liquid. Buffer = 0.02M Sodium Phosphate, 0.25M NaCl with 0.1% sodium azide.
Storage and Stability
Maintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Analysis Note
Control
Brain
Brain
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Li Zhu et al.
The Journal of biological chemistry, 288(44), 32050-32063 (2013-09-21)
Recent studies link synaptojanin 1 (synj1), the main phosphoinositol (4,5)-biphosphate phosphatase (PI(4,5)P2-degrading enzyme) in the brain and synapses, to Alzheimer disease. Here we report a novel mechanism by which synj1 reversely regulates cellular clearance of amyloid-β (Aβ). Genetic down-regulation of
Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation.
Wanxia He, Yifeng Lu, Isam Qahwash, Xiang-You Hu, Ansi Chang, Riqiang Yan
Nature Medicine null
Beta-secretase activity increases with aging in human, monkey, and mouse brain.
Fukumoto, H; Rosene, DL; Moss, MB; Raju, S; Hyman, BT; Irizarry, MC
The American Journal of Pathology null
7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.
Devi, L; Ohno, M
Neuropsychopharmacology null
Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization.
Zou, L; Wang, Z; Shen, L; Bao, GB; Wang, T; Kang, JH; Pei, G
Cell research null
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service